Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

NXL 12.23.2024

Full Press ReleaseSEC FilingsOur NXL Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
  • 12.23.2024 - Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
  • 11.26.2024 - New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Recent Filings

  • 01.10.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
  • 11.08.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
  • 11.01.2024 - 8-K Current report
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com